Market by Product, Application, End-user, and Country | Forecast 2021-2028
Triton’s research report
insinuates that the Middle East and Africa’s pharmaceutical continuous
manufacturing market is expected to foster growth in revenue at a compound
annual growth rate of 9.97% through the years 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries considered for
analysis in this market are:
• The United Arab Emirates
• Turkey
• South Africa
• Saudi Arabia
• Rest of Middle East & Africa
The Middle East and Africa
region is estimated to offer lucrative opportunities for prominent market
players due to the rising target population, growth in the demand for
pharmaceutical products, and enhanced healthcare infrastructure. In Saudi
Arabia, the pharmaceutical industry is among the largest in GCC countries, with
drugs manufactured abroad accounting for most of the market.
Additionally, several reforms
have been introduced by the government to fuel the growth of the pharma
industry. For instance, the government launched 100 percent FDI in the sector
that would surge the total local production of pharmaceutical products across
the country. Therefore, the growing government efforts to limit pharmaceutical
spending and encourage local production is expected to motivate the growth of
the pharmaceutical continuous manufacturing market across Saudi Arabia over the
assessed period.
On the other hand, the pharma
sector is likely to witness significant growth to meet a surging population’s
changing needs in the United Arab Emirates. Moreover, the country has high
import levels, which has compelled the government to augment the local
manufacturing of pharmaceutical products in the country. Besides, the
government authorities are also concentrating on attracting foreign pharma
companies to set up and extend their presence across the country. As stated
above, these factors are anticipated to amplify the pharmaceutical continuous
manufacturing market’s progress across the United Arab Emirates.
Pfizer Inc is a
biopharmaceutical company involved in developing, manufacturing, and
distributing several products, including medicines, consumer healthcare
products, and vaccines. Its comprehensive product portfolio includes products
used to treat conditions, such as cardiovascular disease, infection, cancer,
tissue repair, orphan diseases, and genitourinary disorders. The company’s
continuous manufacturing plant is an innovative, technologically advanced
facility dedicated to tablet production. It has operations in multiple regions,
including Middle East and Africa region.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. PORTER’S
FIVE FORCES MODEL
2.1.1. THREAT
OF NEW ENTRANTS
2.1.2. THREAT
OF SUBSTITUTE PRODUCTS
2.1.3. BARGAINING
POWER OF BUYERS
2.1.4. BARGAINING
POWER OF SUPPLIERS
2.1.5. COMPETITIVE
RIVALRY
2.2. IMPACT
OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
2.3. MARKET
ATTRACTIVENESS INDEX
2.4. VENDOR
SCORECARD
2.5. KEY
INSIGHTS
2.6. MARKET
DRIVERS
2.6.1. RISE
IN INITIATIVES BY REGULATORY AUTHORITIES FOR THE ADOPTION OF CONTINUOUS
MANUFACTURING
2.6.2. SURGING
ACCEPTANCE OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
2.6.3. RISING
HEALTHCARE EXPENDITURE
2.7. MARKET
RESTRAINTS
2.7.1. LACK
OF DEMAND FOR PCM SYSTEMS IN UNDERDEVELOPED ECONOMIES
2.7.2. RISING
CUSTOMER EXPECTATIONS FOR BETTER MEDICINES
2.8. MARKET
OPPORTUNITIES
2.8.1. INCREASING
OPPORTUNITIES IN THE UNTAPPED EMERGING ECONOMIES
2.8.2. SURGE
IN THE MANUFACTURING OF LARGE MOLECULES AND BIOLOGICS
3. MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY
PRODUCT
3.1. INTEGRATED
CONTINUOUS SYSTEM
3.2. SEMI-CONTINUOUS
SYSTEM
3.3. CONTROL
& SOFTWARE
4. MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY APPLICATION
4.1. FINAL
DRUG PRODUCT MANUFACTURING
4.2. API
MANUFACTURING
5. MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY
END-USER
5.1. PHARMACEUTICAL
COMPANIES
5.2. CONTRACT
MANUFACTURING ORGANIZATIONS
5.3. OTHER
END-USERS
6. PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET - MIDDLE EAST AND AFRICA
6.1. COUNTRY
ANALYSIS
6.1.1. SAUDI
ARABIA
6.1.2. UNITED
ARAB EMIRATES
6.1.3. TURKEY
6.1.4. SOUTH
AFRICA
6.1.5. REST
OF MIDDLE EAST & AFRICA
7. COMPANY
PROFILE
7.1. HOSOKAWA
MICRON CORPORATION
7.2. GEA
GROUP AG
7.3. LB
BOHLE MASCHINEN + VERFAHREN GMBH
7.4. THERMO
FISHER SCIENTIFIC INC
7.5. SIEMENS
HEALTHINEERS
7.6. ELI
LILLY & COMPANY
7.7. PFIZER
INC
7.8. GLATT
GMBH
7.9. SYNTEGON
(FORMERLY BOSCH PACKAGING TECHNOLOGY)
7.10. GEBRUDER
LODIGE MASCHINENBAU GMBH
7.11. KORSCH
AG
7.12. COPERION
GMBH
7.13. MUNSON
MACHINERY COMPANY
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.1.1. OBJECTIVES
OF STUDY
8.1.2. SCOPE
OF STUDY
8.2. SOURCES
OF DATA
8.2.1. PRIMARY
DATA SOURCES
8.2.2. SECONDARY
DATA SOURCES
8.3. RESEARCH
METHODOLOGY
8.3.1. EVALUATION
OF PROPOSED MARKET
8.3.2. IDENTIFICATION
OF DATA SOURCES
8.3.3. ASSESSMENT
OF MARKET DETERMINANTS
8.3.4. DATA
COLLECTION
8.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
TABLE 2: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028 (IN $ MILLION)
TABLE 3: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 4: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028 (IN $ MILLION)
TABLE 5: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $ MILLION)
FIGURE 1: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 2: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2021-2028 (IN
$ MILLION)
FIGURE 3: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2021-2028 (IN $
MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2021-2028 (IN $
MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2021-2028
(IN $ MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2021-2028 (IN $
MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS,
2021-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)
FIGURE 10: SAUDI ARABIA PHARMACEUTICAL CONTINUOUS
MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 11: UNITED ARAB EMIRATES PHARMACEUTICAL CONTINUOUS
MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 12: TURKEY PHARMACEUTICAL CONTINUOUS MANUFACTURING
MARKET 2021-2028 (IN $ MILLION)
FIGURE 13: SOUTH AFRICA PHARMACEUTICAL CONTINUOUS
MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 14: REST OF MIDDLE EAST AND AFRICA PHARMACEUTICAL
CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)